An interventional study of Multiple Micronutrients and Standard Antenatal Vitamin in Angiogenesis, Fetal Weight and Pregnancy Related, sponsored by Dr Cipto Mangunkusumo General Hospital. Active, not recruiting at 1 site in Indonesia. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-16.
Sponsored by Dr Cipto Mangunkusumo General Hospital · Not applicable, Interventional, and Treatment
Multiple micronutrients play an important role during pregnancy, since the decidualization and implantation phases. It has an impact on placentation and remodeling of blood vessels. The optimal early pregnancy conditions accompanied by great angiogenesis and vasculogenesis factors will influence fetal growth. This study aims to determine the effect of maternal multiple micronutrient supplementation on angiogenesis factors, vasculogenesis factors, and fetal biometry. It is a clustered randomized controlled trial that aims to determine the impact of maternal micronutrient supplementation on PlGF levels, sFlt-1/PlGF ratio, mean pulsatility index of uterine artery, and fetal biometry (head circumference, femur length, and estimated fetal weight percentile). The target population for the study was all pregnant women who underwent antenatal check-ups at community health centers in DKI Jakarta.
17 studies on the registry are indexed under Fetal Weight; 7 are open to participants now.
Browse Fetal Weight studies →Dr Cipto Mangunkusumo General Hospital is the lead sponsor of 39 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Multiple micronutrient 2. Calcium Carbonat 766 mg 3. Vitamin D3 5000 IU 4. DHA 300 mg
Dietary Supplement: Multiple Micronutrients
Standard antenatal vitamins
Drug: Standard Antenatal Vitamin
1. Multiple micronutrient 2. Calcium Carbonat 766 mg 3. Vitamin D3 5000 IU 4. DHA 300 mg
Standard Antenatal Vitamin given in Community Health Centers
PlGF levels
Examination of angiogenesis factors in both research groups, using venous blood to measure Placental Growth Factor (PlGF) levels
Time frame: It was carried out at gestational age: 1. Trimester 1: 8-14 weeks. 2. Trimester 2: 20-26 weeks.
sFlt-1/PlGF ratio
Examination of the balance of angiogenesis factors in both groups, using venous blood to measure the ratio of soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor (s-Flt-1/PlGF),
Time frame: 20-26 weeks of gestation
mean pulsatility index of uterine artery
Examination of vasculogenesis factors by measuring the mean Pulsatility Index of bilateral uterine arteries
Time frame: 1. Trimester 1 : 8-14 weeks. 2. Trimester 2 : 20-26 weeks.
Head circumference
Head circumference based on ultrasonography
Time frame: 20-26 weeks of gestation
Femur length
Femur length based on ultrasonography
Time frame: 20-26 weeks of gestation
Estimated fetal weight
Estimated fetal weight based on ultrasonography
Time frame: 20-26 weeks of gestation
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr Cipto Mangunkusumo General Hospital